Intrinsic Value of S&P & Nasdaq Contact Us

Glaukos Corporation GKOS NYSE

NYSE • Healthcare • Medical - Devices • US • USD

SharesGrow Score
52/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$143.44
+19%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Glaukos Corporation (GKOS) has a negative trailing P/E of -35.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 278.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.81%, forward earnings yield 0.36%. PEG 2.42.

Criteria proven by this page:

  • VALUE (92/100, Pass) — analyst target implies upside (+19%).
  • Forward P/E 278.8 — analysts expect a return to profitability with estimated EPS of $0.43 for FY2027.
  • PEG Ratio 2.42 — above 2.0 suggests expensive relative to earnings growth.
  • Trailing Earnings Yield -2.81% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.36% as earnings recover.
  • Analyst consensus target $143.44 (+19% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 52/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
52/100
SG Score
View full scorecard →
VALUE
92/100
Price-to-Earnings & upside
Proven by this page
FUTURE
79/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
55/100
→ Income
~
GROWTH
58/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — GKOS

Valuation Multiples
P/E (TTM)-35.6
Forward P/E278.8
PEG Ratio2.42
Forward PEG2.42
P/B Ratio10.19
P/S Ratio13.31
EV/EBITDA-46.5
Per Share Data
EPS (TTM)$-3.26
Forward EPS (Est.)$0.43
Book Value / Share$11.41
Revenue / Share$8.82
FCF / Share$-0.39
Yields & Fair Value
Earnings Yield-2.81%
Forward Earnings Yield0.36%
Dividend Yield0.00%
Analyst Target$143.44 (+19%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 249.8 -2.34 9.63 9.87 -
2017 -9,585.6 94.04 6.38 5.54 -
2018 -151.8 -0.01 11.31 10.85 -
2019 131.9 -0.63 3.02 8.59 -
2020 -27.8 0.04 5.02 14.89 -
2021 -41.6 0.69 3.51 7.02 -
2022 -20.9 -0.22 3.91 7.33 -
2023 -28.6 -0.87 8.34 12.23 -
2024 -54.0 150.23 10.31 20.63 -
2025 -34.4 -1.87 9.84 12.73 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $0.12 $114.4M $4.52M 4%
2017 $0.00 $159.25M $-92K -0.1%
2018 $-0.37 $181.28M $-12.95M -7.1%
2019 $0.37 $236.98M $15.42M 6.5%
2020 $-2.70 $224.96M $-120.35M -53.5%
2021 $-1.07 $294.01M $-49.59M -16.9%
2022 $-2.09 $282.86M $-99.2M -35.1%
2023 $-2.78 $314.71M $-134.66M -42.8%
2024 $-2.77 $383.48M $-146.37M -38.2%
2025 $-3.28 $507.44M $-187.69M -37%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.54 $-0.67 – $-0.38 $613.25M $610.3M – $616.15M 9
2027 $0.43 $0.26 – $0.60 $782.72M $764.36M – $812.03M 9
2028 $1.55 $1.16 – $2.11 $1.02B $1.02B – $1.02B 6
2029 $2.62 $2.51 – $2.71 $1.29B $1.25B – $1.33B 4
2030 $4.32 $4.14 – $4.47 $1.51B $1.46B – $1.55B 2
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message